Curi RMB Capital LLC Purchases 7,597 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Curi RMB Capital LLC increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 19.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,715 shares of the company’s stock after purchasing an additional 7,597 shares during the quarter. Curi RMB Capital LLC owned about 0.05% of CRISPR Therapeutics worth $2,195,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Cetera Investment Advisers boosted its stake in CRISPR Therapeutics by 451.3% in the first quarter. Cetera Investment Advisers now owns 34,100 shares of the company’s stock valued at $2,324,000 after acquiring an additional 27,915 shares during the last quarter. CWM LLC boosted its stake in CRISPR Therapeutics by 11,871.1% in the second quarter. CWM LLC now owns 22,386 shares of the company’s stock valued at $1,209,000 after acquiring an additional 22,199 shares during the last quarter. Capital Advisors Inc. OK boosted its stake in CRISPR Therapeutics by 8.1% in the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock valued at $14,122,000 after acquiring an additional 22,583 shares during the last quarter. Granite Bay Wealth Management LLC bought a new position in CRISPR Therapeutics in the second quarter valued at approximately $2,375,000. Finally, International Assets Investment Management LLC acquired a new stake in CRISPR Therapeutics in the third quarter worth $1,825,000. 69.20% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now directly owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the completion of the transaction, the chief executive officer now owns 196,540 shares of the company’s stock, valued at $10,931,554.80. The trade was a 13.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 35,382 shares of company stock worth $1,917,679 in the last quarter. 4.10% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $47.25 on Friday. The firm has a 50-day moving average of $47.88 and a 200-day moving average of $52.04. CRISPR Therapeutics AG has a one year low of $43.42 and a one year high of $91.10. The company has a market cap of $4.03 billion, a PE ratio of -16.70 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. The business had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter in the previous year, the firm posted ($1.41) EPS. Analysts expect that CRISPR Therapeutics AG will post -5.2 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on CRSP shares. Barclays cut their target price on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Truist Financial cut their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Needham & Company LLC restated a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, Rodman & Renshaw started coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They set a “buy” rating and a $90.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and an average price target of $74.94.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.